Croda leverages Volufiline following surging demand for non-invasive skin-plumping solutions
The product was originally developed by Sederma (now part of Croda) and traditionally positioned as a natural, plant-derived active for visibly plumping areas that lose volume with age.
FRANCE – Croda is set to harness the surge in consumer concern over GLP‑1–related facial volume loss to drive renewed growth for its heritage beauty active Volufiline, reframing the ingredient as a topical solution for restoring facial fullness.
The company’s repositioning pairs renewed technical storytelling with rising social and search interest, helping brands formulate topical solutions that promise a non‑invasive route to restoring facial fullness.
Volufiline, the trade name for an anhydrous, oil-like solution rich in sarsasapogenin, a plant-derived phytosterol (cholesterol-like molecule) extracted from Anemarrhena asphodeloides.
Croda is now treating it as a growth lever within its Beauty portfolio by reframing the ingredient around a newly salient consumer need: counteracting the hollowed, aged look that can follow rapid weight loss.
The company says this approach shows how “innovation can generate significant new commercial opportunities decades after launch,” by combining fresh product development with the strategic repositioning of established actives.
The commercial logic rests on a clear market signal: widespread use of GLP‑1 receptor agonists (such as semaglutide and dual GLP‑1/GIP agents) has intensified public awareness of facial aesthetic side effects from rapid fat loss.
Clinical and survey data indicate that weight loss from these therapies can disproportionately reduce fat in the midface, under‑eye, and temporal regions, leading to infraorbital hollowing, temporal concavity, and an overall impression of accelerated facial ageing.
This has created a ready audience for non‑surgical options, including topical volumizers, as consumers and clinicians look for ways to preserve or restore facial volume during and after GLP‑1 treatment.
Croda is explicitly connecting Volufiline to this trend, arguing that growing awareness of “facial volume loss, driven in part by the increasing popularity of GLP‑1 treatments, has created demand for innovative, non‑invasive cosmetic solutions.”pmc.ncbi.nlm.nih+3
Croda points to independent trend analysis showing sharp growth in online searches and social media discussion around Volufiline, especially in facial skincare and eye care contexts.
The ingredient has also benefited from high‑profile media coverage: in June 2026, Cosmopolitan labeled Volufiline “TikTok’s new ‘It’ skincare ingredient,” underscoring its viral status among beauty consumers.
Brand adoption reinforces the narrative. Deciem (part of Estée Lauder) has used Volufiline as the trade name for a product in The Ordinary range, while other brands, such as SeoulCeuticals, have launched serums highlighting Volufiline’s plumping positioning alongside complementary actives.
For Croda, Volufiline’s revival is a concrete example of how repositioning legacy actives can unlock new revenue streams without requiring entirely new molecules.
The company highlights the active as part of a broader strategy to accelerate growth in Beauty by identifying fresh opportunities across its portfolio and pairing them with new product development.croda+1
For formulators and brand owners, the opportunity lies in aligning product concepts and claims with the GLP‑1 volume‑loss narrative: emphasizing visible plumping, restoration of facial fullness, and support for consumers managing rapid weight‑loss–related aesthetic changes.
Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE.
